sector medic suppli devic
messag disappoint perform rais number difficult
question includ whether confus fda rp commun realli
blame sharp deceler busi whether revenu
growth impli guidanc repres new lower baselin compani
long-term visibl issu still limit today point
inclin answer ye former latter lower pt
maintain buy rate
rp confus short circuit otherwis strong year one question got
repeatedli yesterday whether believ fallout fda physician
commun regard impella rp post approv studi realli culprit
shortfal skeptic part investor like driven part fact
mani done check quarter heard physician
left-sid impella util unlik affect check also
suggest physician took letter stride sens distract
nois surround rp ambigu fda languag bandwidth
issu consum sale forc combin drive weaker procedur volum
march bear might argu deceler protect pci case
vs indic market satur pushback util impella
set hypothesi explain europ japan slow
time concurr deceler across multipl market point rp
culprit view fda megaphon reach far beyond
go manag indic thursday call procedur
volum acceler april remain depress rel compani jan/
feb run rate encourag sign effort assuag concern
posit impact final commun
agenc lay full find investig state
march press releas see fda alreadi agre point
post approv studi includ two distinct patient group recov right patient
met inclus criteria rp pma studi salvag patient alreadi
cardiogen shock hour prior rp implant surviv recov
right cohort similar surviv report pma studi surviv
salvag group proper interpret data fewer
patient get rp view rather patient exhibit sign right heart
failur receiv hemodynam support condit deterior
messag central physician educ effort right
left-sid support mani year present also note
surviv recov right cohort compar favor limit clinic data avail
either ecmo centrimag manag expect final fda
physician commun letter clarifi issu releas end
number move lower confid long-term growth potenti remain
unchang model call revenu
previous forecast assum growth bottom
rebound rp issu move rearview mirror comp
eas factor believ could drive acceler cours year
includ fda approv new impella surgic pump step
invest sale forc estim current impella surgic pump
compani fastest grow product domest volum
yoy earli feedback germani posit meanwhil
made number chang sale forc respons stumbl
ad two new territori expand resourc dedic call heart team
page analyst certif import disclosur
facilit deeper penetr account compani expect add rep per
quarter run rate
long-term continu see top line grower
one question manag sidestep yesterday call whether
growth impli midpoint guidanc repres new normal vs
gain compani post past year want comment
yet understand view given variabl play near-term
hear anyth thursday lead us believ busi model
broken long-term opportun impella materi reduc absent
march slowdown sens manag like would guid someth
approach mid-to-high growth street consensu impli
longer expect gain year reach level current base case assum least
modest reacceler growth gradual moder thereaft
one potenti long-term growth driver remain absent project
stemi conjunct yesterday earn releas announc fda
approv studi design stemi dtu pivot trial studi random
patient either immedi reperfus delay reperfus minut
cardiac unload impella cp primari endpoint infarct size percent
lv mass measur day use cardiac mri trial also power look
number secondari endpoint includ composit clinic outcom
howev intend file indic expans shorter-term
primari endpoint hand although essenti match hope
regard studi design disappoint compani estim timelin
complet manag assum enrol requir year
complet think like conservat built estim initi
forecast make hard assign valu stemi opportun time
view think worth note howev trial steer committe includ
verit kol across intervent cardiolog univers
see strong indic potenti game-chang natur approach
treat patient
lower price target take account
revis estim recent peer group multipl compress expect
share remain penalti box next month thought yesterday stock
action vs flat show fair amount nervous quarter
alreadi bake notic increas interest stori late investor
given under-perform ytd vs part continu
view differenti med-tech growth stori given combin larg
limit competit strong margin profil result certainli
disappoint compani perform maintain buy rate
page analyst certif import disclosur
leader mechan circulatori support dedic enabl safer
treatment high-risk patient cardiovascular diseas recov injur heart
muscl estim patient receiv one compani famili impella
heart pump year yet believ scratch surfac impella
long-term potenti estim market opportun includ
stemi see long runway growth level compani match
impella smallest heart pump world design provid temporari
hemodynam support patient undergo high-risk procedur whose cardiac
function compromis sinc impella first receiv approv
impella famili pump use support ten thousand peopl
abiom revenu grow compound-annual-growth-rate period go forward expect
ramp penetr protect pci cardiogen shock indic drive
continu strong growth compani still earli inning
capit intern opportun impella well recent guidelin
chang germani entri japanes market provid ampl momentum
go forward model call grow total revenu compound-annual-growth-rate
combin strong margin clean balanc sheet limit competit
view one best growth stori med-tech
share trade ntm revenu estim high end
multipl rang high-growth peer smid-cap med-tech group believ
abiom uniqu combin top line growth potenti compound-annual-growth-rate
profit gm om make compani difficult valu base
tradit metric result employ discount cash flow methodolog deriv
price target assum wacc termin growth rate
calcul forward npv per share previous target
equat previous multipl forward ntm sale estim
signific potenti upsid price target current level assign abiom
buy rate
downsid risk rate valuat includ potenti impella adopt
fall short street forecast pipelin setback clinic failur weaken abiom
long-term outlook faster-than-expect progress potenti impella competitor
premium valuat leav littl margin error view
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
servic
revenu geographi
 unit
 unit indic
compani report guggenheim secur llc estim
page analyst certif import disclosur
